A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma

NCT02857569 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Stage III/IV Melanoma

Interventions

DRUG: Ipilimumab IT
DRUG: Ipilimumab IV
DRUG: Nivolumab IV

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris